15.15 USD
↘ 0.22 (1.43%)AT CLOSE (11:59 AM EDT)
Q32 Bio Inc. Common Stock
QTTBNASDAQ • USD
14.95
↘ 0.20 (1.32%)
POST MARKET (AS OF 07:35 PM EDT)
Post Market
AS OF 07:35 PM EDT
14.95
↘ 0.20 (1.32%)
Market: CLOSED
Shares of Q32 Bio Inc. Common Stock (QTTB) are trading at $15.15. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (31.9%) and a bullish Golden Cross on the moving averages. QTTB is fairly valued relative to its sector peers based on current multiples.
Technical & fundamental data as of Aug 14, 2026.
Open?$15.45
High?$15.47
Low?$14.93
Prev. Close?$15.37
Volume?313.3K
Avg. Volume?1.9M
VWAP?$15.14
Rel. Volume?0.16x
Bid / Ask
Bid?$14.79 × 600
Ask?$15.15 × 200
Spread?$0.36
Midpoint?$14.97
Valuation & Ratios
Market Cap?451.0M
Shares Out?29.8M
Float?12.3M
Float %?51.9%
P/E Ratio?13.35
P/B Ratio?4.26
EPS?$1.13
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Address
830 WINTER STREET
WALTHAM, MA 02451
Phone: 781-999-0232
WALTHAM, MA 02451
Phone: 781-999-0232
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?65
Short Sent.?21
Piotroski F-Score?0/9Weak
Altman Z-Score?26.64Safe
Confidence?48%Low
Short InterestSqueeze Risk
Short % of Float?24.38%Squeeze Risk
Short Interest?3.0M
Days to Cover?3.8
Free Float12.3M
Avg Daily Volume795.0K
Settlement Date2026-07-31
Financial Health
Current Ratio?20.30Strong
Quick Ratio?20.30Strong
Cash Ratio?19.68Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score60/100
P/E?13.4CHEAP▾
Peers100
S&P86
P/B?4.26FAIR▾
Peers100
S&P42
P/S?8.39HIGH▾
Peers100
S&P11
P/FCF?N/A▾
EV/EBITDA?15.8FAIR▾
Peers100
S&P45
EV/Sales?6.42HIGH▾
Peers100
S&P24
Returns & Efficiency
ROE?31.9%STRONG▾
Peers50
S&P81
ROA?29.2%STRONG▾
Peers50
S&P97
Cash Flow & Enterprise
FCF?$-19828000
Enterprise Value?$344.7M
Fundamentals ratios updated end of day